Actively Recruiting

Age: 18Years +
All Genders
NCT05428345

A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Led by Takeda · Updated on 2025-10-06

600

Participants Needed

1

Research Sites

218 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main aim of the study is to observe adult participants in South Korea that are being treated with vedolizumab injected just under the skin (subcutaneous or SC) to treat ulcerative colitis (UC) or Crohn's disease (CD) who have had an in-adequate response with, lost response to, or had too many side effects in response to either conventional therapy or a Tumor Necrosis Factor-alpha (TNF-α) antagonist. This study will observe the side effects and potential benefit to UC and CD participants related to vedolizumab SC treatment with data collection from medical files. There is no treatment involved in this study, this is only an observational review of current collected data relating to adults in South Korea with UC or CD treated with vedolizumab SC.

CONDITIONS

Official Title

A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults with moderately to severely active ulcerative colitis or Crohn's disease
  • History of inadequate response, loss of response, or intolerance to conventional therapy or TNF-alpha antagonists
  • Evidence of therapeutic benefit after at least two vedolizumab intravenous infusions
Not Eligible

You will not qualify if you...

  • Hypersensitivity to vedolizumab or its excipients, including symptoms like dyspnea, bronchospasm, urticaria, flushing, or increased heart rate
  • Active severe infections such as tuberculosis, cytomegalovirus, sepsis, listeriosis, or opportunistic infections like Progressive Multifocal Leukoencephalopathy (PML)
  • Contraindication to vedolizumab subcutaneous injection as per product label

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Donggguk University Ilsan Hospital

Goyang-si, Gyeonggi-do, South Korea, 10326

Actively Recruiting

Loading map...

Research Team

T

Takeda Contact

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here